View source for STBT5:Fibromatosis colli

{{DISPLAYTITLE:Fibromatosis colli}}

[[STBT5:Table_of_Contents|Soft Tissue and Bone Tumours (Who Classification, 5th ed.)]]

Primary Author(s)*

Kathleen Schieffer, PhD, FACMG
==WHO Classification of Disease==

{| class="wikitable"
!Structure
!Disease
|-
|Book
|Soft Tissue and Bone Tumours (5th ed.)
|-
|Category
|Soft tissue tumours
|-
|Family
|Fibroblastic and myofibroblastic tumours
|-
|Type
|Fibromatosis colli
|-
|Subtype(s)
|N/A
|}

==Related Terminology==

{| class="wikitable"
|+
|Acceptable
|N/A
|-
|Not Recommended
|Sternocleidomastoid tumour of infancy; pseudotumour of infancy; congenital muscular torticollis
|}

==Gene Rearrangements==
None
{| class="wikitable sortable"
|-
!Driver Gene!!Fusion(s) and Common Partner Genes!!Molecular Pathogenesis!!Typical Chromosomal Alteration(s)
!Prevalence -Common >20%, Recurrent 5-20% or Rare <5% (Disease)
!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
!Established Clinical Significance Per Guidelines - Yes or No (Source)
!Clinical Relevance Details/Other Notes
|-
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|}
==Individual Region Genomic Gain/Loss/LOH==
None
{| class="wikitable sortable"
|-
!Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s)
!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
!Established Clinical Significance Per Guidelines - Yes or No (Source)
!Clinical Relevance Details/Other Notes
|-
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|}
==Characteristic Chromosomal or Other Global Mutational Patterns==
None
{| class="wikitable sortable"
|-
!Chromosomal Pattern
!Molecular Pathogenesis
!Prevalence - 
Common >20%, Recurrent 5-20% or Rare <5% (Disease)
!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
!Established Clinical Significance Per Guidelines - Yes or No (Source)
!Clinical Relevance Details/Other Notes
|-
|N/A
|N/A
|vN/A
|
|N/A
|N/A
|}
==Gene Mutations (SNV/INDEL)==
None
{| class="wikitable sortable"
|-
!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence -
Common >20%, Recurrent 5-20% or Rare <5% (Disease)
!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T  
!Established Clinical Significance Per Guidelines - Yes or No (Source)
!Clinical Relevance Details/Other Notes
|-
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|}Note: A more extensive list of mutations can be found in [https://www.cbioportal.org/ <u>cBioportal</u>], [https://cancer.sanger.ac.uk/cosmic <u>COSMIC</u>], and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.
==Epigenomic Alterations==
None
==Genes and Main Pathways Involved==
None
{| class="wikitable sortable"
|-
!Gene; Genetic Alteration!!Pathway!!Pathophysiologic Outcome
|-
|N/A
|N/A
|N/A
|}
==Genetic Diagnostic Testing Methods==
Not Applicable
==Familial Forms==
Not Applicable
==Additional Information==
The role of genetics in the development of fibromatosis colli has not yet been determined.
==Links==
None
==References==
Not Applicable
<references />

==Notes==
<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page.  If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the [[Leadership|''<u>Associate Editor</u>'']] or other CCGA representative.  When pages have a major update, the new author will be acknowledged at the beginning of the page, and those who contributed previously will be acknowledged below as a prior author. 

<nowiki>*</nowiki>''Citation of this Page'': “Fibromatosis colli”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/STBT5:Fibromatosis colli</nowiki>.
[[Category:STBT5]]
[[Category:DISEASE]]
[[Category:Diseases F]]